These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32362235)

  • 1. Understanding the binding affinity of noscapines with protease of SARS-CoV-2 for COVID-19 using MD simulations at different temperatures.
    Kumar D; Kumari K; Jayaraj A; Kumar V; Kumar RV; Dass SK; Chandra R; Singh P
    J Biomol Struct Dyn; 2021 Apr; 39(7):2659-2672. PubMed ID: 32362235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Binding Mechanism and Pharmacology Comparative Analysis of Noscapine for Repurposing against SARS-CoV-2 Protease.
    Kumar N; Sood D; van der Spek PJ; Sharma HS; Chandra R
    J Proteome Res; 2020 Nov; 19(11):4678-4689. PubMed ID: 32786685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DFT and docking studies of designed conjugates of noscapines & repurposing drugs: promising inhibitors of main protease of SARS-CoV-2 and falcipan-2.
    Kumar A; Kumar D; Kumar R; Singh P; Chandra R; Kumari K
    J Biomol Struct Dyn; 2022 Apr; 40(6):2600-2620. PubMed ID: 33140690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
    Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A
    Molecules; 2020 May; 25(11):. PubMed ID: 32485894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.
    Fakhar Z; Faramarzi B; Pacifico S; Faramarzi S
    J Biomol Struct Dyn; 2021 Oct; 39(16):6171-6183. PubMed ID: 32741312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
    Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
    PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors.
    Ibrahim MAA; Abdelrahman AHM; Hussien TA; Badr EAA; Mohamed TA; El-Seedi HR; Pare PW; Efferth T; Hegazy MF
    Comput Biol Med; 2020 Nov; 126():104046. PubMed ID: 33065388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Finding potent inhibitors for COVID-19 main protease (M
    Motiwale M; Yadav NS; Kumar S; Kushwaha T; Choudhir G; Sharma S; Singour PK
    J Biomol Struct Dyn; 2022 Mar; 40(4):1534-1545. PubMed ID: 33030102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of antiviral drugs based on inhibitors of the SARS-COV-2 main protease].
    Sulimov AV; Shikhaliev KS; Pyankov OV; Shcherbakov DN; Chirkova VY; Ilin IS; Kutov DC; Tashchilova AS; Krysin MY; Krylskiy DV; Stolpovskaya NV; Volosnikova EA; Belenkaya SV; Sulimov VB
    Biomed Khim; 2021 May; 67(3):259-267. PubMed ID: 34142533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.
    Abu-Saleh AAA; Awad IE; Yadav A; Poirier RA
    Phys Chem Chem Phys; 2020 Oct; 22(40):23099-23106. PubMed ID: 33025993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Promising inhibitors of main protease of novel corona virus to prevent the spread of COVID-19 using docking and molecular dynamics simulation.
    Kumar D; Kumari K; Vishvakarma VK; Jayaraj A; Kumar D; Ramappa VK; Patel R; Kumar V; Dass SK; Chandra R; Singh P
    J Biomol Struct Dyn; 2021 Aug; 39(13):4671-4685. PubMed ID: 32567995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitussive noscapine and antiviral drug conjugates as arsenal against COVID-19: a comprehensive chemoinformatics analysis.
    Kumar N; Awasthi A; Kumari A; Sood D; Jain P; Singh T; Sharma N; Grover A; Chandra R
    J Biomol Struct Dyn; 2022 Jan; 40(1):101-116. PubMed ID: 32815796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virtual screening, ADME/T, and binding free energy analysis of anti-viral, anti-protease, and anti-infectious compounds against NSP10/NSP16 methyltransferase and main protease of SARS CoV-2.
    Maurya SK; Maurya AK; Mishra N; Siddique HR
    J Recept Signal Transduct Res; 2020 Dec; 40(6):605-612. PubMed ID: 32476594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of chymotrypsin-like protease inhibitors of SARS-CoV-2
    Khan SA; Zia K; Ashraf S; Uddin R; Ul-Haq Z
    J Biomol Struct Dyn; 2021 Apr; 39(7):2607-2616. PubMed ID: 32238094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based lead optimization of herbal medicine rutin for inhibiting SARS-CoV-2's main protease.
    Huynh T; Wang H; Luan B
    Phys Chem Chem Phys; 2020 Nov; 22(43):25335-25343. PubMed ID: 33140777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virtual Double-System Single-Box: A Nonequilibrium Alchemical Technique for Absolute Binding Free Energy Calculations: Application to Ligands of the SARS-CoV-2 Main Protease.
    Macchiagodena M; Pagliai M; Karrenbrock M; Guarnieri G; Iannone F; Procacci P
    J Chem Theory Comput; 2020 Nov; 16(11):7160-7172. PubMed ID: 33090785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug repurposing for coronavirus (COVID-19):
    Elmezayen AD; Al-Obaidi A; Şahin AT; Yelekçi K
    J Biomol Struct Dyn; 2021 May; 39(8):2980-2992. PubMed ID: 32306862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.